Accuray's TomoHD Treatment System is a comprehensive solution that efficiently handles clinical indications of any complexity. The system offers both TomoDirect and TomoHelical treatment modes to allow clinicians to deliver treatment options for a range of clinical indications and enables daily 3D CT imaging of every patient, prior to each treatment, to maximize treatment accuracy. The TomoDirect modality is efficient in applying multiple targeted radiation beams to the tumor for more routine cases while TomoHelical is designed for more complex cases, delivering radiation throughout multiple 360 degree gantry rotations.
"The combination of TomoDirect and TomoHelical on the TomoHD System creates a single efficient and clinically flexible radiation therapy treatment solution," said Omar Dawood M.D., M.P.H., senior vice president, Global Medical Affairs, Accuray Incorporated. "By expanding the reach of TomoTherapy technology, the addition of TomoDirect allows physicians to offer the highest quality treatments tailored for each individual patient's specific clinical needs. The increase in global adoption of TomoDirect is a testament to the clinical benefits of the technology."
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation
|SOURCE Accuray Incorporated|
Copyright©2010 PR Newswire.
All rights reserved